SWTX SPRINGWORKS THERAPEUTICS INC revenue, earnings and financials
For the quarter ended March 31, 2025, SPRINGWORKS THERAPEUTICS INC reported revenue of $49.1M (up 133.7% from a year earlier), net income of −$83.2M and diluted EPS of −$1.11; over the last four quarters revenue was $220M and net income −$254M; for the fiscal year ended December 2024 revenue was $192M, up 3417.3% on the year before.
SWTX annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $192M, gross profit n/a, operating income −$278M, net income −$258M (margin -134.7%), EPS −$3.48
- Fiscal year ended Dec 2023: revenue $5.45M, gross profit n/a, operating income −$343M, net income −$325M (margin -5968.5%), EPS −$5.15
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$281M, net income −$277M (margin n/a), EPS −$5.21
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$173M, net income −$174M (margin n/a), EPS −$3.59
SWTX quarterly revenue and earnings
- Quarter ended Mar 31, 2025: revenue $49.1M (up 133.7% year over year), net income −$83.2M, EPS −$1.11
- Quarter ended Dec 31, 2024 (from the annual report): revenue $61.5M (up 1030.0% year over year), net income −$77.3M, EPS −$1.04
- Quarter ended Sep 30, 2024: revenue $49.3M, net income −$53.5M, EPS −$0.72
- Quarter ended Jun 30, 2024: revenue $59.7M, net income −$39.9M, EPS −$0.54
- Quarter ended Mar 31, 2024: revenue $21.0M, net income −$87.4M, EPS −$1.18
- Quarter ended Dec 31, 2023 (from the annual report): revenue $5.45M, net income −$94.3M, EPS −$1.45
- Quarter ended Sep 30, 2023: revenue $0, net income −$79.4M, EPS −$1.27
- Quarter ended Jun 30, 2023: revenue $0, net income −$77.9M, EPS −$1.25
- Quarter ended Mar 31, 2023: revenue $0, net income −$73.4M, EPS −$1.18
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$74.2M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$72.4M, EPS −$1.37
- Quarter ended Jun 30, 2022: revenue n/a, net income −$69.1M, EPS −$1.41
- Quarter ended Mar 31, 2022: revenue n/a, net income −$61.8M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$56.1M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$41.0M, EPS n/a
- Quarter ended Jun 30, 2021: revenue n/a, net income −$47.0M, EPS n/a
- Quarter ended Mar 31, 2021: revenue n/a, net income −$29.8M, EPS n/a
SWTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$176M, share buybacks $8.44M
- Fiscal year ended Dec 2023: operating cash flow −$223M, share buybacks $2.80M
- Fiscal year ended Dec 2022: operating cash flow −$162M, share buybacks $1.34M
- Fiscal year ended Dec 2021: operating cash flow −$128M, share buybacks $0
SWTX balance sheet
- Mar 31, 2025: cash $63.8M, total assets $505M, total liabilities $88.0M, shareholders' equity $417M
- Dec 31, 2024: cash $69.8M, total assets $587M, total liabilities $106M, shareholders' equity $481M
- Sep 30, 2024: cash $84.5M, total assets $609M, total liabilities $76.3M, shareholders' equity $533M
- Jun 30, 2024: cash $79.9M, total assets $617M, total liabilities $60.6M, shareholders' equity $557M
- Mar 31, 2024: cash $118M, total assets $657M, total liabilities $89.4M, shareholders' equity $567M
- Dec 31, 2023: cash $176M, total assets $726M, total liabilities $99.6M, shareholders' equity $626M
- Sep 30, 2023: cash $98.9M, total assets $468M, total liabilities $72.8M, shareholders' equity $395M
- Jun 30, 2023: cash $115M, total assets $517M, total liabilities $65.9M, shareholders' equity $451M
What is SWTX's revenue?
SPRINGWORKS THERAPEUTICS INC reported $220M of revenue over its last four quarters, through March 31, 2025.
Is SWTX profitable?
No. SPRINGWORKS THERAPEUTICS INC lost $254M over the last four quarters.
What is SWTX's EPS?
Diluted earnings per share over the last four quarters were −$3.41; −$1.11 in the latest quarter.